IL6 and episodic ataxia type 2: Likewise, in the French MYCOVID study, although introducing a triazole did not modify mortality in patients with proven or probable CAPA, the authors also focused on the possible benefit of prophylaxis or pre-emptive strategies for high-risk patients, including those receiving dexamethasone combined with anti-IL6 [10].